chemotherapy - Articles and news items

FDA approves new combination treatment for acute myeloid leukaemia

Industry news / 4 May 2017 / Niamh Marriott, Junior Editor

The drug is approved for use in combination with LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML…

FDA to review Mylan and Biocon’s biosimilar application

Industry news / 17 February 2017 / Niamh Marriott, Digital Editor

The US Food and Drug Administration (FDA) has accepted Mylan and Biocon’s biologics license application for MYL-1401H, a proposed biosimilar to Neulasta…

Life-extending breast cancer drug approved by NICE

Industry news / 3 November 2016 / Niamh Louise Marriott, Digital Content Producer

NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer…

Roche’s cancer immunotherapy drug has longer OS vs. chemotherapy

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events were consistent with what has […]

Onivyde receives positive CHMP opinion for pancreatic cancer treatment

Industry news / 25 July 2016 / Niamh Louise Marriott, Digital Content Producer

The positive opinion is based on a pivotal Phase 3 study showing that Onivyde combined with chemotherapy significantly increased overall survival in patients with metastatic pancreatic cancer…

Combining soft-tissue cancer drugs improves survival

Industry news / 21 July 2016 / Niamh Louise Marriott, Digital Content Producer

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased survival by nearly a year in patients with lethal soft-tissue cancer…

Blood cancer study yields disappointing results

Industry news / 19 July 2016 / Niamh Louise Marriott

Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+